AURO-ONDANSETRON INJECTION SOLUTION

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE)

可用日期:

AURO PHARMA INC

ATC代码:

A04AA01

INN（国际名称）:

ONDANSETRON

剂量:

2MG

药物剂型:

SOLUTION

组成:

ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 2MG

给药途径:

INTRAVENOUS

每包单位数:

15G/50G

处方类型:

Prescription

治疗领域:

5-HT3 RECEPTOR ANTAGONISTS

產品總結:

Active ingredient group (AIG) number: 0131120004; AHFS:

授权状态:

APPROVED

授权日期:

2019-08-14

产品特点

ONDANSETRON INJECTION BP/AURO-ONDANSETRON INJECTION PRODUCT MONOGRAPH
PAGE 1 OF 46
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR ONDANSETRON INJECTION BP
Sterile Solution, 2 mg / mL ondansetron (as ondansetron hydrochloride
dihydrate), Intravenous
BP
PR AURO-ONDANSETRON INJECTION
Ondansetron Injection
Sterile Solution, 2 mg / mL ondansetron (as ondansetron hydrochloride
dihydrate), Intravenous
BP
Antiemetic (5-HT3 receptor antagonist)
ATC code A04AA01
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
CANADA
Date of Initial Authorization:
February 7, 2017
Date of Revision:
March 9, 2023
Submission Control Number: 268107
ONDANSETRON INJECTION BP/AURO-ONDANSETRON INJECTION PRODUCT MONOGRAPH
PAGE 2 OF 46
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Cardiovascular,
Myocardial Ischemia and Coronary Artery Spasm
03/2023
7 WARNINGS AND PRECAUTIONS, Special Populations,
7.1.1 Pregnant Women
02/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1 INDICATIONS
....................................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2 Geriatrics (≥65 years of age)
.......................................................................................
4
2 CONTRAINDICATIONS
.......................................................................................................
5
4 DOSAGE AND ADMINISTRATION
.......................................................................